Trial Profile
Rapamycin Utility for secondary prevention of skin tumors in renal transplant recipients with recurrent squamous cell carcinoma. (Utilidad de la Rapamicina para la prevención secundaria de tumores cutáneos en trasplantados renales con recidiva de carcinoma espinocelular)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Aug 2012
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Ciclosporin; Tacrolimus
- Indications Renal transplant rejection; Skin cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TUMORAPA-N
- 22 Aug 2012 New trial record
- 26 Jul 2012 Primary endpoint 'Disease-occurrence-rate' has been met.
- 26 Jul 2012 Primary endpoint 'Disease-free-survival-duration' has been met.